Pluvicto 1 000 MBq/mL solution for injection/infusion
*Company:
Novartis Ireland LimitedStatus:
UpdatedLegal Category:
Product subject to restricted prescription (C)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Updated on 19 June 2025
File name
Pluvicto_REG PIL_PF24-0233_08.05.2025_clean_IPHA.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
Updated on 19 June 2025
File name
Pluvicto REGSPC_IE and MT_PF24-0233_08.05.2025_clean_IPHA.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 11 - Dosimetry
- Change to section 12 - Instructions for preparation of radiopharmaceuticals
Legal category:Product subject to restricted prescription (C)
File name
A406923 Novartis Pluvicto A5 Patient Booklet-d8.pdf
Reasons for updating
- Add New Doc
Updated on 29 April 2025
File name
Pluvicto_REG SPC_PF24-0060_IE MT clean_IPHA_April2024.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Updated on 29 April 2025
File name
Pluvicto_REG PIL_PF24-0060_IE MT_April2024_clean_IPHA.pdf
Reasons for updating
- New PIL for new product
Novartis Ireland Limited
Address:
Vista Building, Elm Park Business Park, Merrion Road, Dublin 4, IrelandMedical Information E-mail:
medinfo.dublin@novartis.comTelephone:
+353 1 2601255Fax:
+353 1 2601263